The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma

American Journal of Pathology

Volumn 182, Issue 4, 2013, Pages 1163-1170

  Lichner, Zsuzsanna ^a,b   Scorilas, Andreas ^c   White, Nicole M A ^a,b   Girgis, Andrew H ^a   Rotstein, Lora ^a   Wiegand, Kimberly C ^d   Latif, Ashraf ^a   Chow, Christina ^e   Huntsman, David ^d,e   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Genetic Pathology Evaluation Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RETINOBLASTOMA BINDING PROTEIN 2;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPUTER MODEL; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; EXOME; FEMALE; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY CORTEX; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CARCINOMA, RENAL CELL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; NUCLEAR PROTEINS; PROGNOSIS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875147024     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.01.007     Document Type: Article

References (52)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. E.P. Simard, E.M. Ward, R. Siegel, and A. Jemal Cancers with increasing incidence trends in the United States: 1999 through 2008 [published correction appears in CA Cancer J Clin 2012, 62:277] CA Cancer J Clin 62 2012 118 128
3. J.R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F.-M. Duh, I. Lubensky, D.R. Duan, C. Florence, R. Pozzatti, M.M. Walther, N.H. Bander, H.B. Grossman, H. Branch, S. Pomer, J.D. Brooks, W.B. Isaacs, M.I. Lerman, B. Zbar, and W.M. Linehan Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
4. W.G. Kaelin Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer Clin Cancer Res 10 18 Pt 2 2004 6290S 6295S
5. D.C. Hargreaves, and G.R. Crabtree ATP-dependent chromatin remodeling: genetics, genomics and mechanisms Cell Res 21 2011 396 420
6. B.G. Wilson, and C.W. Roberts SWI/SNF nucleosome remodellers and cancer Nat Rev Cancer 11 2011 481 492
7. C.W. Roberts, M.M. Leroux, M.D. Fleming, and S.H. Orkin Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5 Cancer Cell 2 2002 415 425
8. S. Jones, T.L. Wang, IeM. Shih, T.L. Mao, K. Nakayama, R. Roden, R. Glas, D. Slamon, L.A. Diaz Jr., B. Vogelstein, K.W. Kinzler, V.E. Velculescu, and N. Papadopoulos Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
9. A. Katagiri, K. Nakayama, M.T. Rahman, M. Rahman, H. Katagiri, N. Nakayama, M. Ishikawa, T. Ishibashi, K. Iida, H. Kobayashi, Y. Otsuki, S. Nakayama, and K. Miyazaki Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma Mod Pathol 25 2012 282 288
10. K.C. Wiegand, S.P. Shah, O.M. Al-Agha, Y. Zhao, K. Tse, T. Zeng, J. Senz, M.K. McConechy, M.S. Anglesio, S.E. Kalloger, W. Yang, A. Heravi-Moussavi, R. Giuliany, C. Chow, J. Fee, A. Zayed, L. Prentice, N. Melnyk, G. Turashvili, A.D. Delaney, J. Madore, S. Yip, A.W. McPherson, G. Ha, L. Bell, S. Fereday, A. Tam, L. Galletta, P.N. Tonin, D. Provencher, D. Miller, S.J. Jones, R.A. Moore, G.B. Morin, A. Oloumi, N. Boyd, S.A. Aparicio, IeM. Shih, A.M. Mes-Masson, D.D. Bowtell, M. Hirst, B. Gilks, M.A. Marra, and D.G. Huntsman ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 2010 1532 1543
11. K.C. Wiegand, A.F. Lee, O.M. Al-Agha, C. Chow, S.E. Kalloger, D.W. Scott, C. Steidl, S.M. Wiseman, R.D. Gascoyne, B. Gilks, and D.G. Huntsman Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas J Pathol 224 2011 328 333
12. D.W. Parsons, M. Li, X. Zhang, S. Jones, R.J. Leary, J.C. Lin, S.M. Boca, H. Carter, J. Samayoa, C. Bettegowda, G.L. Gallia, G.I. Jallo, Z.A. Binder, Y. Nikolsky, J. Hartigan, D.R. Smith, D.S. Gerhard, D.W. Fults, S. VandenBerg, M.S. Berger, S.K. Marie, S.M. Shinjo, C. Clara, P.C. Phillips, J.E. Minturn, J.A. Biegel, A.R. Judkins, A.C. Resnick, P.B. Storm, T. Curran, Y. He, B.A. Rasheed, H.S. Friedman, S.T. Keir, R. McLendon, P.A. Northcott, M.D. Taylor, P.C. Burger, G.J. Riggins, R. Karchin, G. Parmigiani, D.D. Bigner, H. Yan, N. Papadopoulos, B. Vogelstein, K.W. Kinzler, and V.E. Velculescu The genetic landscape of the childhood cancer medulloblastoma Science 331 2011 435 439
13. J. Huang, Y.L. Zhao, Y. Li, J.A. Fletcher, and S. Xiao Genomic and functional evidence for an ARID1A tumor suppressor role Genes Chromosomes Cancer 46 2007 745 750
14. I. Varela, P. Tarpey, K. Raine, D. Huang, C.K. Ong, P. Stephens, H. Davies, D. Jones, M.L. Lin, J. Teague, G. Bignell, A. Butler, J. Cho, G.L. Dalgliesh, D. Galappaththige, C. Greenman, C. Hardy, M. Jia, C. Latimer, K.W. Lau, J. Marshall, S. McLaren, A. Menzies, L. Mudie, L. Stebbings, D.A. Largaespada, L.F. Wessels, S. Richard, R.J. Kahnoski, J. Anema, D.A. Tuveson, P.A. Perez-Mancera, V. Mustonen, A. Fischer, D.J. Adams, A. Rust, W. Chan-on, C. Subimerb, K. Dykema, K. Furge, P.J. Campbell, B.T. Teh, M.R. Stratton, and P.A. Futreal Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma [published correction appears in Nature 2012, 484:130] Nature 469 2011 539 542
15. X. Wang, N.G. Nagl Jr., S. Flowers, D. Zweitzig, P.B. Dallas, and E. Moran Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors Int J Cancer 112 2004 636
16. K. Wang, J. Kan, S.T. Yuen, S.T. Shi, K.M. Chu, S. Law, T.L. Chan, Z. Kan, A.S. Chan, W.Y. Tsui, S.P. Lee, S.L. Ho, A.K. Chan, G.H. Cheng, P.C. Roberts, P.A. Rejto, N.W. Gibson, D.J. Pocalyko, M. Mao, J. Xu, and S.Y. Leung Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer Nat Genet 43 2011 1219 1223
17. R. Bétous, A.C. Mason, R.P. Rambo, C.E. Bansbach, A. Badu-Nkansah, B.M. Sirbu, B.F. Eichman, and D. Cortez SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication Genes Dev 26 2012 151 162
18. M.S. Isakoff, C.G. Sansam, P. Tamayo, A. Subramanian, J.A. Evans, C.M. Fillmore, X. Wang, J.A. Biegel, S.L. Pomeroy, J.P. Mesirov, and C.W. Roberts Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation Proc Natl Acad Sci U S A 102 2005 17745 17750
19. I. Oruetxebarria, F. Venturini, T. Kekarainen, A. Houweling, L.M. Zuijderduijn, A. Mohd-Sarip, R.G. Vries, R.C. Hoeben, and C.P. Verrijzer P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells J Biol Chem 279 2004 3807 3816
20. D. Trouche, C. Le Chalony, C. Muchardt, M. Yaniv, and T. Kouzarides RB and hbrm cooperate to repress the activation functions of E2F1 Proc Natl Acad Sci U S A 94 1997 11268 11273
21. N.G. Nagl Jr., A. Patsialou, D.S. Haines, P.B. Dallas, G.R. Beck Jr., and E. Moran The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest Cancer Res 65 2005 9236 9244
22. J. Caramel, F. Quignon, and O. Delattre RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1 Cancer Res 68 2008 6154 6161
23. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.P. Goldberg, C. Sander, and N. Schultz The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2 2012 401 404
24. A.H. Girgis, V.V. Iakovlev, B. Beheshti, J. Bayani, J.A. Squire, A. Bui, M. Mankaruos, Y. Youssef, B. Khalil, H. Khella, M. Pasic, and G.M. Yousef Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma Cancer Res 72 2012 5273 5284
25. S.M. Metias, E. Lianidou, and G.M. Yousef MicroRNAs in clinical oncology: at the crossroads between promises and problems J Clin Pathol 62 2009 771 776
26. D. Wuttig, S. Zastrow, S. Fussel, M.I. Toma, M. Meinhardt, K. Kalman, K. Junker, J. Sanjmyatav, K. Boll, J. Hackermuller, A. Rolle, M.O. Grimm, and M.P. Wirth CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases Int J Cancer 131 2012 E693 E704
27. A.B. Stillebroer, P.F. Mulders, O.C. Boerman, W.J. Oyen, and E. Oosterwijk Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy Eur Urol 58 2010 75 83
28. S.G. Kroeze, J.S. Vermaat, A. van Brussel, H.H. van Melick, E.E. Voest, T.G. Jonges, P.J. van Diest, J. Hinrichs, J.L. Bosch, and J.J. Jans Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients Eur J Cancer 46 2010 3375 3382
29. L. Gossage, and T. Eisen Alterations in VHL as potential biomarkers in renal-cell carcinoma Nat Rev Clin Oncol 7 2010 277 288
30. H. Faragalla, Y.M. Youssef, A. Scorilas, B. Khalil, N.M. White, S. Mejia-Guerrero, H. Khella, M.A. Jewett, A. Evans, Z. Lichner, G. Bjarnason, L. Sugar, M.I. Attalah, and G.M. Yousef The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma J Mol Diagn 14 2012 385 392
31. V.V. Iakovlev, M. Gabril, W. Dubinski, A. Scorilas, Y.M. Youssef, H. Faragalla, K. Kovacs, F. Rotondo, S. Metias, A. Arsanious, A. Plotkin, A.H. Girgis, C.J. Streutker, and G.M. Yousef Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study Lab Invest 92 2012 46 56
32. M. Diamandis, N.M. White, and G.M. Yousef Personalized medicine: marking a new epoch in cancer patient management Mol Cancer Res 8 2010 1175 1187
33. N.M. White, and G.M. Yousef Translating molecular signatures of renal cell carcinoma into clinical practice J Urol 186 2011 9 11
34. G.L. Dalgliesh, K. Furge, C. Greenman, L. Chen, G. Bignell, A. Butler, H. Davies, S. Edkins, C. Hardy, C. Latimer, J. Teague, J. Andrews, S. Barthorpe, D. Beare, G. Buck, P.J. Campbell, S. Forbes, M. Jia, D. Jones, H. Knott, C.Y. Kok, K.W. Lau, C. Leroy, M.L. Lin, D.J. McBride, M. Maddison, S. Maguire, K. McLay, A. Menzies, T. Mironenko, L. Mulderrig, L. Mudie, S. O'Meara, E. Pleasance, A. Rajasingham, R. Shepherd, R. Smith, L. Stebbings, P. Stephens, G. Tang, P.S. Tarpey, K. Turrell, K.J. Dykema, S.K. Khoo, D. Petillo, B. Wondergem, J. Anema, R.J. Kahnoski, B.T. Teh, M.R. Stratton, and P.A. Futreal Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes Nature 463 2010 360 363
35. Z. Lichner, S. Mejia-Guerrero, M. Ignacak, A. Krizova, T.T. Bao, A.H. Girgis, Y.M. Youssef, and G.M. Yousef Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways Am J Pathol 180 2012 1675 1687
36. N.M. White, H.W. Khella, J. Grigull, S. Adzovic, Y.M. Youssef, R.J. Honey, R. Stewart, K.T. Pace, G.A. Bjarnason, M.A. Jewett, A.J. Evans, M. Gabril, and G.M. Yousef miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215 Br J Cancer 105 2011 1741 1749
37. N.M. White, T.T. Bao, J. Grigull, Y.M. Youssef, A. Girgis, M. Diamandis, E. Fatoohi, M. Metias, R.J. Honey, R. Stewart, K.T. Pace, G.A. Bjarnason, and G.M. Yousef miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation J Urol 186 2011 1077 1083
38. A. Martinez, P. Fullwood, K. Kondo, T. Kishida, M. Yao, E.R. Maher, and F. Latif Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis Mol Pathol 53 2000 137 144
39. X. Xu, Y. Hou, X. Yin, L. Bao, A. Tang, L. Song, F. Li, S. Tsang, K. Wu, H. Wu, W. He, L. Zeng, M. Xing, R. Wu, H. Jiang, X. Liu, D. Cao, G. Guo, X. Hu, Y. Gui, Z. Li, W. Xie, X. Sun, M. Shi, Z. Cai, B. Wang, M. Zhong, J. Li, Z. Lu, N. Gu, X. Zhang, L. Goodman, L. Bolund, J. Wang, H. Yang, K. Kristiansen, M. Dean, Y. Li, and J. Wang Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor Cell 148 2012 886 895
40. H. Zhang, Y. Zhai, Z. Hu, C. Wu, J. Qian, W. Jia, F. Ma, W. Huang, L. Yu, W. Yue, Z. Wang, P. Li, Y. Zhang, R. Liang, Z. Wei, Y. Cui, W. Xie, M. Cai, X. Yu, Y. Yuan, X. Xia, X. Zhang, H. Yang, W. Qiu, J. Yang, F. Gong, M. Chen, H. Shen, D. Lin, Y.X. Zeng, F. He, and G. Zhou Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers Nat Genet 42 2010 755 758
41. N. Lin, C. Di, K. Bortoff, J. Fu, P. Truszkowski, P. Killela, C. Duncan, R. McLendon, D. Bigner, S. Gregory, and D.C. Adamson Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma Mol Cancer Res 10 2012 208 217
42. J.C. Shultz, R.W. Goehe, C.S. Murudkar, D.S. Wijesinghe, E.K. Mayton, A. Massiello, A.J. Hawkins, P. Mukerjee, R.L. Pinkerman, M.A. Park, and C.E. Chalfant SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells Mol Cancer Res 9 2011 889 900
43. Y. Gui, G. Guo, Y. Huang, X. Hu, A. Tang, S. Gao, R. Wu, C. Chen, X. Li, L. Zhou, M. He, Z. Li, X. Sun, W. Jia, J. Chen, S. Yang, F. Zhou, X. Zhao, S. Wan, R. Ye, C. Liang, Z. Liu, P. Huang, C. Liu, H. Jiang, Y. Wang, H. Zheng, L. Sun, X. Liu, Z. Jiang, D. Feng, J. Chen, S. Wu, J. Zou, Z. Zhang, R. Yang, J. Zhao, C. Xu, W. Yin, Z. Guan, J. Ye, H. Zhang, J. Li, K. Kristiansen, M.L. Nickerson, D. Theodorescu, Y. Li, X. Zhang, S. Li, J. Wang, H. Yang, J. Wang, and Z. Cai Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat Genet 43 2011 875 878
44. B. Guan, T.L. Wang, and IeM. Shih ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers [published correction appears in Cancer Res 2012, 72:3116] Cancer Res 71 2011 6718 6727
45. N.G. Nagl Jr., D.R. Zweitzig, B. Thimmapaya, G.R. Beck Jr., and E. Moran The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest Cancer Res 66 2006 1289 1293
46. A.H. Girgis, V.V. Iakovlev, B. Beheshti, J. Bayani, J.A. Squire, A. Bui, M. Mankaruos, Y. Youssef, B. Khalil, H. Khella, M. Pasic, and G.M. Yousef Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma Cancer Res 72 2012 5273 5284
47. J. Mallen-St Clair, R. Soydaner-Azeloglu, K.E. Lee, L. Taylor, A. Livanos, Y. Pylayeva-Gupta, G. Miller, R. Margueron, D. Reinberg, and D. Bar-Sagi EZH2 couples pancreatic regeneration to neoplastic progression Genes Dev 26 2012 439 444
48. T. Neff, A.U. Sinha, M.J. Kluk, N. Zhu, M.H. Khattab, L. Stein, H. Xie, S.H. Orkin, and S.A. Armstrong Polycomb repressive complex 2 is required for MLL-AF9 leukemia Proc Natl Acad Sci U S A 109 2012 5028 5033
49. G. Ren, S. Baritaki, H. Marathe, J. Feng, S. Park, S. Beach, P.S. Bazeley, A.B. Beshir, G. Fenteany, R. Mehra, S. Daignault, F. Al-Mulla, E. Keller, B. Bonavida, I. de la Serna, and K.C. Yeung Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer Cancer Res 72 2012 3091 3104
50. G12D acute myeloid leukemia Oncogene 2012 [Epub ahead of press]
51. M. Takawa, K. Masuda, M. Kunizaki, Y. Daigo, K. Takagi, Y. Iwai, H.S. Cho, G. Toyokawa, Y. Yamane, K. Maejima, H.I. Field, T. Kobayashi, T. Akasu, M. Sugiyama, E. Tsuchiya, Y. Atomi, B.A. Ponder, Y. Nakamura, and R. Hamamoto Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker Cancer Sci 102 2011 1298 1305
52. A. Yamada, S. Fujii, H. Daiko, M. Nishimura, T. Chiba, and A. Ochiai Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus Int J Oncol 38 2011 345 353